<DOC>
	<DOCNO>NCT02210091</DOCNO>
	<brief_summary>The study purpose : - To assess incidence FVIII inhibitory antibody 6 month twice weekly prophylactic treatment BAX 855 50 exposure day ( EDs ) , whichever occur last . - To compare pharmacokinetic ( PK ) parameter ADVATE . - To assess hemostatic efficacy prophylaxis treatment bleed episode . - To evaluate safety immunogenicity .</brief_summary>
	<brief_title>BAX 855 Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( Factor VIII ( FVIII ) &lt; 1 % ) determine central laboratory . &lt; 12 year old time screen . Participants age ≥6 &lt; 12 year age previously treat plasmaderived and/or recombinant Factor VIII ( rFVIII ) concentrate ( ) minimum 150 exposure day ( EDs ) ( base participant 's medical record ) . Participants &lt; 6 year age previously treat plasmaderived and/or rFVIII concentrate ( ) least 50 EDs ( base participant 's medical record ) . Participant human immunodeficiency virus ( HIV ) negative ; HIV positive stable disease CD4+ count ≥200 cells/mm^3 , confirmed central laboratory . Participant and/or legal representative accepts prophylactic treatment period 6 month . Participant and/or legal representative willing able comply requirement protocol . Participant detectable FVIII inhibitory antibody ( ≥0.4 Bethesda Units ( BU ) use Nijmegen modification Bethesda assay ) confirm central laboratory screening . Participant history FVIII inhibitory antibody ( ≥0.4 BU use Nijmegen modification Bethesda assay ≥0.6 BU use Bethesda assay ) time prior screening . Participant known hypersensitivity towards mouse hamster protein , polyethylene glycol ( PEG ) , Tween 80 . Participant diagnose inherit acquire hemostatic defect hemophilia A ( eg , qualitative platelet defect von Willebrand 's disease ) . Participant 's platelet count &lt; 100,000/μL . Participant severe chronic hepatic dysfunction ( eg , ≥5 time upper limit normal ( ULN ) alanine aminotransferase ( ALT ) , confirmed central laboratory screening , document international normalized ratio ( INR ) &gt; 1.5 ) . Participant severe renal impairment ( serum creatinine &gt; 1.5 time ULN ) . Participant schedule receive course study , immunomodulating drug ( eg , corticosteroid agent dose equivalent hydrocortisone &gt; 10 mg/day , αinterferon ) antiretroviral chemotherapy . Participant current recent ( &lt; 30 day ) use PEGylated drug prior study participation schedule use drug study participation . Participant participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . Participant medical , psychiatric , cognitive illness recreational drug/alcohol use , opinion Investigator , would affect participant safety compliance . Participant 's legal representative member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>